The U.S. Government owns a new invention for an improved live-attenuated vaccine targeting Respiratory Syncytial Virus (RSV) and is now offering it for licensing. The technology involves a vaccine developed by altering certain RSV genes to create a version of the virus that stays stable and is weakened enough to be safe for use as a vaccine. This vaccine could potentially help protect infants, young children, and older adults from serious respiratory diseases caused by RSV and is designed to be administered intranasally. The National Institute of Allergy and Infectious Diseases is looking for commercial partners to develop and evaluate this vaccine further.
Simple Explanation
The government has a new tool to help stop a germ that makes people's noses and lungs sick, especially in babies and grandparents, and they're looking for companies to help make it into a medicine you can spray up your nose.